Limitations of controlled augmentation trials in schizophrenia
- 15 July 1997
- journal article
- review article
- Published by Elsevier in Biological Psychiatry
- Vol. 42 (2) , 138-143
- https://doi.org/10.1016/s0006-3223(96)00295-8
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Risperidone in the treatment of schizophreniaAmerican Journal of Psychiatry, 1994
- The Case for Establishing a Register of Randomised Controlled Trials of Mental Health CareThe British Journal of Psychiatry, 1994
- The Pharmacoepidemiology of Treatment-Refractory Schizophrenia*The Canadian Journal of Psychiatry, 1992
- Treatment of the Neuroleptic-Nonresponsive Schizophrenic PatientSchizophrenia Bulletin, 1992
- NALTREXONE IN CHRONIC NEGATIVE SCHIZOPHRENIAClinical Neuropharmacology, 1992
- When Symptoms Persist: Choosing Among Alternative Somatic Treatments for SchizophreniaSchizophrenia Bulletin, 1991
- Enhancement of recovery from psychiatric illness by methylfolateThe Lancet, 1990
- Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenicsBiological Psychiatry, 1989
- Lithium Combined with Haloperidol in Schizophrenic PatientsThe British Journal of Psychiatry, 1988
- Double-blind Comparison of Alprazolam, Diazepam, and Placebo for the Treatment of Negative Schizophrenic SymptomsArchives of General Psychiatry, 1988